Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319210 | 0.75 | ALDH1A1 (0.50) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| SCHEMBL10874600 | 0.69 | ALDH1A1 (0.41) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| Lithium SCHEMBL30416555 | 0.69 | ALDH1A1 (0.89) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| SCHEMBL21834206 | 0.69 | HSD17B10 (0.43) | — | |
| SCHEMBL7195373 | 0.65 | ALDH1A1 (0.38) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL10340047 | 0.65 | ALDH1A1 (1.00) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| SCHEMBL18889428 | 0.65 | ALDH1A1 (1.00) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 | |
| SCHEMBL20781 | 0.65 | — | — | |
| SCHEMBL1332087 | 0.65 | — | — | |
| SCHEMBL10665040 | 0.63 | ALDH1A1 (0.42) | ALDH1A1ALOX15TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2920155-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | MTNR1B, TNNC1, PER2 | ALDH1A1 1629/4885ALOX15 524/4885TSHR 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.